Effect of the Intelligent Lipid Management Decision-support System on 1-year LDL-C Target Achievement in Ischemic Stroke or TIA Patients Under Evolocumab Treatment in China

Prior treatment

• Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date;
• Any prior use of Evolocumab or other PCSK9 inhibitor treatments within the past 6 months prior to the screening date;

Other illness

• Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.;
• Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis);
• Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders;

Other

• Silent cerebral infarction without signs and symptoms;
• Life expectancy \<12 months or unable to complete the research for other reasons as of the screening date;
• Refusal to participate in the enrollment survey.

• Age≥18 years as of the screening date;
• Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;
• Prescribed Evolocumab at physician's discretion;
• Signed informed consent.